Ionis Pharmaceuticals - IONS Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IONS shares.
View IONS analyst ratings or view top-rated stocks.

10 equities research analysts have issued 1 year target prices for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $27.00 to $65.00. On average, they expect the company's stock price to reach $48.10 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

Ionis Pharmaceuticals' stock was trading at $30.43 at the beginning of the year. Since then, IONS stock has increased by 48.0% and is now trading at $45.03.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our IONS earnings forecast.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings data on Tuesday, August, 9th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by $0.13. The company had revenue of $134 million for the quarter, compared to the consensus estimate of $142.65 million. Ionis Pharmaceuticals had a negative net margin of 3.18% and a negative trailing twelve-month return on equity of 4.10%. The company's revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.57) earnings per share.

Ionis Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $610.05 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IONS stock can currently be purchased for approximately $45.03.

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $6.39 billion and generates $810 million in revenue each year. The company earns $-28,600,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

The company employs 660 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.